Kala Bio jumped 22% after hours after securing emergency financing that prevents its lender from seizing assets following a default linked to the collapse of its KPI-012 Phase 2 eye disease trial. The two-stage preferred stock deal provides up to $6 million, restructures debts, and brings in turnaround-focused leadership to stabilize operations.